Prophylaxis and proper management with an appropriate anticoagulant can. The incidence of major VTE decreased with increasing rivaroxaban doses in a.
3 Although warfarin is effective in managing and preventing thromboembolic disease over time, its variable pharmacokinetics, its significant potential for drug interactions, its slow onset of effect, and a patient’s genetic factors contribute to its unpredictable response, thus requiring close monitoring for dose initiation and adjustments. The only orally available agent for the long-term management of thromboembolic disease in the U.S.
Detailed dosage guidelines and administration information for Xarelto (rivaroxaban). Prophylaxis of DVT Following Hip or Knee Replacement Surgery (2.6).
The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.
Deep Vein Thrombosis, Recurrent Event warfarin, Coumadin, rivaroxaban, Jantoven, More.
Deep Vein Thrombosis Eliquis, Pradaxa, Lovenox, apixaban, enoxaparin, rivaroxaban, More.
Pregnancy Category C Risk cannot be ruled out.
Pulmonary Embolism Eliquis, Pradaxa, apixaban, rivaroxaban, heparin, dabigatran, More.
CSA Schedule N Not a controlled drug.
In the nonvalvular atrial fibrillation efficacy study XARELTO was taken with the evening meal.
Switching from XARELTO to Anticoagulants other than Warfarin - For patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset, discontinue XARELTO and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next XARELTO dose would have been taken.
The recommended dose of XARELTO is 10 mg taken orally once daily with or without food.
DVT Prophylaxis After Knee or Hip Replacement Surgery Dosing Videos, reprints, and more to help you stay informed about XARELTO.
Last Updated: June 21, 2017 at 16:28:32 ET.
B. Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. Spinal/epidural hematoma.
For US Healthcare Professionals Only.
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.
Proven results across a wide range of patient types in multiple phase 3 trials.
More than 26 million people worldwide have been prescribed XARELTO 1.
All third party trademarks used herein are trademarks of their respective owners.
Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices vary from country to country.
Choose Xarelto for the Treatment, Secondary Prevention of PE & DVT, Help protect your patients from PE/DVT recurrence with fast, effective clot regression.
Access all major studies, including ROCKET AF, XANTUS, EINSTEIN PE/DVT, XAMOS and RECORD. Find out more.
If you are a US visitor, please click here. This website is intended to provide information to an international audience outside the USA, the UK, Austria and Southern African countries including South Africa.
First published, prospective, international, observational study of a NOAC for the treatment and secondary prevention of VTE.
Find out more. A collection of short animated films that help to explain the broad benefits of Xarelto.
See all references for this page.
Summary of Product Characteristics ▶
If no local version of the website is available for your country, you can access the global website. Please choose one of the options below:.
Oral treatment from day 1 offers convenience and enduring protection.
Well-established efficacy and safety in PE /DVT.
If you are visiting from one of the countries below, please click the respective flag for accessing your local website.
DVT Prophylaxis After Knee or Hip Replacement Surgery. Dosing and Administration for DVT Prophylaxis After Knee or Hip Replacement Surgery. XARELTO provides a consistent approach to protecting against deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) after.